

See “5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis” on page 69-78.

**Supplementary Table 1.** Adverse Effects Experienced by Patients Intolerant to 5-ASA

Side effects to 5-ASA	No. (%) (n = 59)
Diarrhea	35 (59.3)
Fever	13 (22.0)
Headache	6 (10.1)
Rash	4 (6.7)
Abdominal pain	2 (3.3)
Others	7 (11.8)

ASA, aminosalicylic acid.

**Supplementary Table 2.** Baseline Characteristics of Patients at Start of Biologics Therapy

Characteristic	Value (n = 108)
Age (yr)	38.5 ± 14.5
Sex, male/female	52 (48.1)/56 (51.8)
Duration of disease (yr)	10.6 ± 16.7
Extent of disease, E/L/R	72 (66.6)/32 (29.6)/4 (3.7)
Partial Mayo score	5.82 ± 1.90
Hemoglobin level (g/dL)	11.90 ± 1.92
Platelet ( $\times 10^3/\mu\text{L}$ )	378.3 ± 122.2
Albumin level (g/dL)	3.50 ± 0.70
Concomitant therapy	
5-ASA	89 (82.4)
IM	62 (57.4)

Values are presented as mean ± SD or number (%).

E, extensive colitis; L, left-sided colitis; R, proctitis; ASA, aminosalicylic acid; IM, immunomodulator.

**Supplementary Table 3.** Risk Factors for Additional Treatment

Risk factor	Additional treatment (n = 23)	No additional treatment (n = 85)	Univariate analysis	Multivariate analysis	
			P-value	OR (95% CI)	P-value
Albumin level (g/dL)	3.68 ± 0.64	3.56 ± 0.72	0.517	-	0.767
5-ASA intolerance	9 (39.1)	11 (12.9)	0.025	3.284 (1.022–10.551)	0.046
Concomitant IM	15 (65.2)	47 (55.2)	0.469	-	0.763

Values are presented as mean ± SD or number (%).

ASA, aminosalicylic acid; IM, immunomodulator.